The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising ...

Causes of portal hypertension can be prehepatic (such as portal vein thrombosis), hepatic (commonly liver cirrhosis and hepatic fibrosis) or posthepatic (such as hepatic vein obstruction).

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...

The global elastography imaging market is experiencing significant growth, with projections indicating that the industry will ...

Increases in Size: On average, patients experienced a 50% increase in penile flaccid length and a 37% increase in girth post-implantation, demonstrating significant anatomical enhancements with Penuma ...

These animals develop cirrhosis, portal hypertension, and HPS at 4–5 weeks ... including ET-1 and NO (Fig. 2). Liver injury stimulates release of ET-1, which increases expression of ET B ...

Crabapple Dental is thrilled to announce that Dr. Sarah Roberts has successfully completed a 12-week course called Molis Coaching. This advanced training has equipped Dr. Roberts with the latest ...

Recent observational studies in Europe, including chronic liver failure acute-on-chronic liver ... each other as patients descend into decompensated cirrhosis.2 Clinically significant portal ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising your blood pressure. This state is called portal hypertension. Portal ...

Two-rat models of cirrhosis and ACLF ... In vivo, Yaq-001 reduced liver injury, progression of fibrosis, portal hypertension, renal dysfunction and mortality of ACLF animals significantly. Significant ...